nelfinavir has been researched along with Adenocarcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V | 1 |
| Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N | 1 |
| Bridgewater, J; Corrie, PG; Hawkins, M; Hurt, CN; Maughan, T; Mukherjee, S; O'Neill, E; Parsons, P; Patel, N; Radhakrishna, G; Sebag-Montefiore, D; Shaw, R; Strauss, VY; Tranter, B; Virdee, PS; Ward, E | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Azoulay, S; Dani, C; Darini, CY; Drici, MD; Hofman, P; Ladoux, A; Martin, P; Obba, S | 1 |
| Adachi, Y; Bandobashi, K; Ikezoe, T; Kobayashi, M; Koeffler, HP; Nishioka, C; Taguchi, H; Takeuchi, S; Takeuchi, T; Yang, Y | 1 |
3 trial(s) available for nelfinavir and Adenocarcinoma
| Article | Year |
|---|---|
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Membrane Proteins; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Radiosurgery; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nelfinavir; Neoplasms, Second Primary; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
4 other study(ies) available for nelfinavir and Adenocarcinoma
| Article | Year |
|---|---|
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Radiosurgery; Treatment Outcome | 2019 |
Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Disease Progression; Drug Screening Assays, Antitumor; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Intestinal Neoplasms; Lopinavir; Mesenchymal Stem Cells; Mice; Mice, SCID; Nelfinavir; Neoplasm Transplantation; Neoplastic Stem Cells; Pyrans; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Down-Regulation; Drug Combinations; Glycogen Synthase Kinases; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nelfinavir; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2006 |